Novartis unveils results from global patient and physician survey disrupting the notion that CML is a solved disease | MarketScreener
of bookmarks Include in my collection of favorite links
New Survey Challenges Idea That CML Is Solved: Novartis Findings
On December 6th, 2023 at 8:48am Eastern Daylight Time.
Novartis shared findings from its CML SUN at the 2023 EHA Hybrid Congress held in Basel.
According to Fabian Lang, MD, Goethe University Hospital, Frankfurt, Germany, a member of the CML SUN Steering Committee and author of the study, the purpose of the CML SUN project was to provide answers to important questions that have not yet been addressed by people with chronic myeloid leukemia and their doctors. These questions include how to approach treatment options, what differences exist in efficacy and tolerance priorities, and how to effectively communicate goals between patients and physicians. Because CML has become a more manageable chronic disease with available treatments, it is crucial to understand the priorities of patients and doctors as they change over time. The findings of the CML SUN project will help us improve the management of CML in the future.
Similar patterns have been found among 11 countries regarding treatment objectives, joint collaboration, and fulfillment with treatment. Specifically, patients aim to halt or decelerate disease advancement, improve or maintain their quality of life, and regulate or minimize adverse effects. On the other hand, physicians prioritize treatment effectiveness.
In different areas of medical care, about half of doctors say they suggest just a single treatment to their patients. Meanwhile, approximately four in ten patients say they only hear about one treatment option from their doctor.
Just a small percentage, around 19% to 26%, of patients say they discuss and decide about treatments together with their doctors. Meanwhile, the majority of physicians, 44% to 48%, claim that they make decisions about treatments on their own, without much involvement from patients. This occurs in all areas of medical treatment.
The majority of patients and doctors express contentment with the effectiveness of the treatments currently available. However, several patients have explained that the treatments they receive negatively impact their quality of life. These negative effects can include feeling tired physically or emotionally, struggling to exercise and keep up with social interactions, and persistently worrying and stressing over the effectiveness of the treatment.
Lisa Machado, who sits on the CML SUN Steering Committee, is the founder of the Canadian CML Network, and is also the executive producer of Healthing.ca. She thinks it is important for people with chronic myeloid leukemia to be open and honest with their doctors. They should talk about their treatment goals, how the medication side effects make them feel, and how they are doing emotionally and mentally. The way we treat CML, a type of cancer, has improved a lot and new medicines mean people can live longer and better lives with the disease. Despite this progress, there is still more to be done. Doctors and patients need to work together more closely to help patients make decisions that are right for them and to understand what quality of life means to them.
The given outcomes are derived from information attained from several countries including Australia, Brazil, Canada, France, Germany, Italy, Japan, South Korea, Spain, UK and USA. The conclusive examination of the information is anticipated to be released later in the year.
Novartis is dedicated to fulfilling its commitment to patients who are fighting chronic myeloid leukemia (CML). The company works tirelessly to develop and provide effective treatments that can improve the lives of those living with this disease. Novartis has made significant strides in CML research and development. One of the most notable achievements is the creation of the drug imatinib, which revolutionized CML treatment. Since its introduction, imatinib has become the standard of care for CML patients worldwide. Beyond imatinib, Novartis has continued to invest in CML research. The company has developed multiple other treatments, including dasatinib and nilotinib, which have been shown to be effective in treating CML patients who are resistant to imatinib. Novartis is also devoted to providing support for CML patients. The company offers educational resources and advocacy programs to help patients manage their disease and improve their quality of life. In short, Novartis is dedicated to advancing CML research and improving the lives of patients. The company will continue to work tirelessly to develop new treatments and provide support for those living with this disease.
For over two decades, Novartis has been dedicated to advancing the scientific understanding and treatment of patients with CML. Our innovative research has substantially improved the lives of many individuals affected by this disease by turning it into a chronic illness. Nevertheless, we are persistently seeking new approaches to tackle CML by investigating new ways to treat patients who may develop resistance or intolerance towards treatments. Beyond this scientific mission, Novartis is equally committed to promoting sustainable access to treatment and works closely with the global CML community.
This update includes statements about potential future events for the investigational or approved products being described. These statements can be recognized by words such as "potential," "will," "may," "could," or similar terms. These statements are based on our beliefs and expectations about future events and are subject to unknown risks and uncertainties. If these risks or uncertainties occur, actual results may differ from what is stated in the forward-looking statements. It is not guaranteed that the investigational or approved products described in this update will be sold in any market or will be successful in the future. The success of these products will depend on several factors, including research and development, regulatory actions, physician and patient preferences, economic conditions, and safety issues. Novartis does not guarantee that the information in this update is accurate or up to date and is not obligated to update any statements in the future.
Novartis is changing the way medicine is used to make people's lives better and longer. Our focus is on making effective medicines that help with the toughest health problems by using innovative research and accessibility strategies. We make it our mission to invest heavily in research and development to discover new treatments. Our team is made up of people from over 140 different countries, all working together to bring Novartis products to approximately 800 million people globally.
Telephone Number: +41 61 324 7944
The following blog section is brought to you by ENP Newswire, with copyright © 2023. Free English version: This blog post is made possible by ENP Newswire, copyright © 2023.
Length of Time
Novartis AG trends analyzed through technical analysis Novartis AG is a company that provides healthcare solutions on a global level. One way to analyze the company's performance is through technical analysis, which looks at the company's stock price and past performance to predict future trends. Technical analysis involves looking at chart patterns, trends, and indicators to identify buy and sell signals. By using this method, investors can make decisions based on the data patterns rather than speculation or personal opinions. When it comes to Novartis AG, technical analysis shows that the company's stock price has been fluctuating between a support level of $85 and a resistance level of $95 over the past year. The moving average convergence divergence (MACD) indicator also reveals that the stock is currently on an upward trend, indicating a potential buying opportunity. However, technical analysis is just one tool used to make investment decisions. It's important to consider other factors such as market trends, financial statements, and industry news before making any investment decisions.
